Literature DB >> 18337555

Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients.

Sandra Quijano1, Antonio López, Ana Rasillo, Susana Barrena, Maria Luz Sánchez, Juan Flores, Carlos Fernández, José María Sayagués, Carlos Salvador Osuna, Nuria Fernández, Marcos González, Pilar Giraldo, Manuel Giralt, Maria Carmen Pérez, José Manuel Martin-Antoran, Oliver Gutiérrez, Luis Perdiguer, Joaquín Díaz Mediavilla, Manuel González Silva, Agustín Asensio Del Rio, Carlos Cerveró, José Luis Guerra, Rosario Butrón, Maria del Carmen García, Julia Almeida, Alberto Orfao.   

Abstract

Limited knowledge exists about the impact of specific genetic abnormalities on the proliferation of neoplastic B cells from chronic lymphoproliferative disorders (B-CLPDs). Here we analyze the impact of cytogenetic abnormalities on the proliferation of neoplastic B cells in 432 B-CLPD patients, grouped according to diagnosis and site of sampling, versus their normal counterparts. Overall, proliferation of neoplastic B cells highly varied among the different B-CLPD subtypes, the greatest numbers of proliferating cells being identified in diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). Compared with normal B cells, neoplastic B-CLPD cells showed significantly increased S + G(2)/M-phase values in mantle cell lymphoma (MCL), B-chronic lymphocytic leukemia (B-CLL), BL, and some DLBCL cases. Conversely, decreased proliferation was observed in follicular lymphoma, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM), and some DLBCL patients; hairy cell leukemia, splenic marginal zone, and MALT-lymphoma patients showed S + G(2)/M phase values similar to normal mature B lymphocytes from LN. Interestingly, in B-CLL and MCL significantly higher percentages of S + G(2)/M cells were detected in BM versus PB and in LN versus BM and PB samples, respectively. In turn, presence of 14q32.3 gene rearrangements and DNA aneuploidy, was associated with a higher percentage of S + G(2)/M-phase cells among LPL/WM and B-CLL cases, respectively.

Entities:  

Mesh:

Year:  2008        PMID: 18337555     DOI: 10.1182/blood-2007-10-119289

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

Authors:  Fabienne McClanahan; John C Riches; Shaun Miller; William P Day; Eleni Kotsiou; Donna Neuberg; Carlo M Croce; Melania Capasso; John G Gribben
Journal:  Blood       Date:  2015-05-15       Impact factor: 22.113

3.  Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.

Authors:  Martin Schmidt-Hieber; María Laura Gutiérrez; Martin Pérez-Andrés; Bruno Paiva; Ana Rasillo; Maria Dolores Tabernero; José Maria Sayagués; Antonio Lopez; Paloma Bárcena; María Luz Sanchez; Norma C Gutiérrez; Jesus F San Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

Review 4.  Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Authors:  Yair Herishanu; Ben-Zion Katz; Andrew Lipsky; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

5.  Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping.

Authors:  E S Costa; C E Pedreira; S Barrena; Q Lecrevisse; J Flores; S Quijano; J Almeida; M del Carmen García-Macias; S Bottcher; J J M Van Dongen; A Orfao
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

6.  Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia.

Authors:  I González-Gascón Y Marín; J A Hernández; A Martín; M Alcoceba; M E Sarasquete; A Rodríguez-Vicente; C Heras; N de Las Heras; R Fisac; A García de Coca; I de la Fuente; M Hernández-Sánchez; I Recio; J Galende; G Martín-Núñez; J M Alonso; J M Hernández-Rivas; M González
Journal:  Biomed Res Int       Date:  2014-03-30       Impact factor: 3.411

7.  Flow Cytometric DNA Ploidy Analysis in Haemato-Lymphoid Neoplasms: An Analysis of 132 Cases.

Authors:  Nishit Gupta; Aditi Mittal; Tina Dadu; Dharma Choudhary; Anil Handoo
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2022-01-01

8.  Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells.

Authors:  Silvia Bruno; Bernardetta Ledda; Claudya Tenca; Silvia Ravera; Anna Maria Orengo; Andrea Nicola Mazzarello; Elisa Pesenti; Salvatore Casciaro; Omar Racchi; Fabio Ghiotto; Cecilia Marini; Gianmario Sambuceti; Andrea DeCensi; Franco Fais
Journal:  Oncotarget       Date:  2015-09-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.